JW Pharmaceutical’s HEMLIBRA proven to alleviate joint 슬롯사이트 지니 in hemophilia A patient

[by Ji, Yong Jun] JW Pharmaceutical revealed on February 20 that research findings indicated the hemophilia A treatment, ‘HEMLIBRA’ improves patients’ quality of life, particularly in relation to 슬롯사이트 지니, published in the international academic journal ‘Haemophilia’.

슬롯사이트 지니 is an innovative novel drug with a mechanism that mimics the lack of blood clotting factor VIII in hemophilia A patients. It utilizes bispecific antibody technology, which simultaneously binds to blood clotting factors IX and X.

It can be used by both antibody patients who have developed resistance to existing treatments (such as factor VIII preparations) and non-antibody patients. Its preventive effect lasts up to four weeks with a single subcutaneous injection. As of June 2024, around 25,000 hemophilia A patients around the world were receiving 슬롯사이트 지니 treatment.

The research team, led by Professor Cedric Hermans of the Catholic University of Louvain in Belgium, conducted a study involving 504 patients with severe hemophilia A who participated in the global phase 3 clinical trial of HEMLIBRA. The team monitored changes in joint and swelling 슬롯사이트 지니 for 78 weeks following the administration of HEMLIBRA to adolescents and adults aged 12 years or older.

Approximately 80% of bleeding episodes in hemophilia patients occur in the joints, which is the primary cause of joint 슬롯사이트 지니. A previous study found that 86% of 381 hemophilia patients with a history of joint bleeding experienced either acute or chronic 슬롯사이트 지니. This 슬롯사이트 지니 not only impacts physical activity but also affects mental health, leading to a decreased quality of life.

The study showed that the percentage of patients reporting 'no or almost no swelling 슬롯사이트 지니' increased from 37.0% before treatment to 84.0% by the 13th week of administration. The proportion of patients who reported ‘no or little joint 슬롯사이트 지니’ rose from 30.0% to 61.0%, and those who indicated ‘no or little 슬롯사이트 지니 and discomfort’ improved from 71.0% to 81.0% over the same period. These 슬롯사이트 지니 relief effects lasted up to 78 weeks.

Notably, in patients who had received preventive treatment with existing factor VIII therapies for more than six months, the percentage of those reporting ‘no or little 슬롯사이트 지니’ related to swelling and 슬롯사이트 지니 increased by 41.7% after 13 weeks of HEMLIBRA administration. Similarly, the percentage of patients experiencing ‘no or little 슬롯사이트 지니’ increased by 29.2%.

“Continuous preventive treatment with HEMLIBRA reduces joint bleeding and intra-articular rebleeding, which likely contributes to alleviating 슬롯사이트 지니 associated with synovial inflammation,” the research team explained. “This suggests that HEMLIBRA preventive treatment can offer additional benefits, such as improved quality of life, beyond the reduced bleeding rate seen with factor VIII preventive treatment.”

“Through this study, we hope that 슬롯사이트 지니 preventive therapy can contribute to improving the quality of life of hemophilia patients, in addition to its function in preventing bleeding,” a JW Pharmaceutical official said.